- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04832750
Depression-Reduction by Accelerated Personalized NeuroModulation and Its Effects on Sleep (DREAMS)
Study Overview
Status
Intervention / Treatment
Detailed Description
Repetitive transcranial magnetic stimulation (rTMS) is a safe and efficacious treatment option for treatment-resistant depression. Advances in rTMS protocols with intermittent theta-burst stimulation (iTBS) have significantly decreased the duration for one single session and thereby enabled accelerated treatment plans with multiple sessions per day, potentially reducing the total treatment duration. Major depressive disorder (MDD) is characterized by impairments in various domains including sleep, impulse control, and interoception. Borderline personality disorder (BPD) is characterized by fear of abandonment, mood swings, and an unstable perception of self and often occurs with comorbid MDD. This comorbidity frequently impedes treatment of the BPD.
In this randomized, placebo-controlled study, 60 patients with treatment-resistant MDD (30 verum group, 30 sham group) and 60 patients with treatment-resistant MDD and comorbid BPD (30 verum group, 30 sham group) will receive two weeks of connectivity-informed iTBS of the left dorsolateral prefrontal cortex (DLPFC; 3 sessions per day, 5 days per week). Before and after the treatment phase, (functional) magnetic resonance imaging (fMRI) will be performed. The effects of iTBS will be tested in four domains: (1) symptom severity (MDD and BPD symptoms), (2) sleep quality (sleep questionnaires and various sleep parameters monitored via an electroencephalography (EEG) headband), (3) neurocognitive effects (vigilance and response inhibition measured with behavioral and fMRI tasks), and (4) interoception (interoceptive attention measured with behavioral and fMRI tasks). Furthermore, before the start of the two-weeks treatment, a single iTBS session ("forecaster session") will be conducted to explore the validity of early symptom/mood responses and hormonal changes for the prediction of the the treatment outcome. Treatment effects will be analyzed within and across patient groups (MDD and MDD + BPD). In addition, domain-specific treatment effects will be analyzed as a function of distinct iTBS targets within the DLPFC.To evaluate pathological biases, the investigators will compare the patients' data with a control group of 30 healthy participants who will also be tested twice (without iTBS).
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: René Hurlemann, Prof.
- Phone Number: 1501 +49 (0)441 9615
- Email: rene.hurlemann@uni-oldenburg.de
Study Contact Backup
- Name: Dirk Scheele, Dr.
- Phone Number: 1508 +49 (0)441 9615
- Email: dirk.scheele@uni-oldenburg.de
Study Locations
-
-
-
Bad Zwischenahn, Germany, 26160
- Recruiting
- Department of Psychiatry, University of Oldenburg
-
Contact:
- Dirk Scheele, PhD
- Phone Number: 1508 +49 441 9615
- Email: Dirk.Scheele@uol.de
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Participant is able to provide consent.
- Diagnosis of major depressive disorder (MDD) according to DSM-V criteria.
- During the current episode, treatment-resistant MDD (at least one failed pharmacological trial of adequate dose and duration)
- For the MDD group with comorbid borderline personality disorder (BPD): diagnosis of BPD according to the Diagnotic Statistical Manual V (DSM-V) criteria.
- For healthy controls: no psychiatric or neurological illness.
Exclusion Criteria:
- For the MDD group without BPD: BPD diagnosis
- The participant does not fulfill requirements for iTBS treatment according to safety guidelines.
- The participant does not fulfill requirements for MRI measurements according to safety guidelines.
- Pregnancy or breast-feeding.
- Acute suicidality.
- Neurological illness (e.g. dementia, Parkinson's disease, chorea huntington, multiple sclerosis).
- increased current risk for epileptic seizure.
- comorbid diagnosis of schizophrenia or psychotic symptoms, bipolar disorder, and substance use disorder within the last 6 months.
- Conditions related to increased intracranial pressure.
- Brain injury or stroke.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Major Depressive Episode
At least one failed pharmaco trial in current episode
|
30 sessions of iTBS over 2 weeks (3 sessions per day, 5 days per week)
|
Major Depressive Episode with comorbid Borderline Personality Disorder
At least one failed pharmaco trial in current episode
|
30 sessions of iTBS over 2 weeks (3 sessions per day, 5 days per week)
|
Healthy Controls
No psychiatric disorders
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in depression severity after the treatment phase
Time Frame: Up to 5 weekdays after the last iTBS treatment session
|
Measured with the Montgomery Asberg Rating Scale (MARDS).
Remission defined as MADRS score (range: 0 to 60) of less than or equal to 10. Response defined as a reduction of at least 50 percent from baseline in MADRS score.
|
Up to 5 weekdays after the last iTBS treatment session
|
Change in BPD severity after the treatment phase
Time Frame: Up to 5 weekdays after the last iTBS treatment session
|
Measured by the Zanarini rating scale for BPD (Zan-BPD, range 0-36).
Remission is defined as score of 9 or less.
Response defined as a decrease from baseline in Zan-BPD score of at least 20 percent of the scoring range, i.e. a reduction of 8 points or more.
|
Up to 5 weekdays after the last iTBS treatment session
|
Changes in neural responses in an interoception task before the first and after the last treatment session
Time Frame: Up to 5 weekdays before the first and after the last treatment session
|
Measured with functional magnetic resonance imaging (fMRI) while performing an interoception task
|
Up to 5 weekdays before the first and after the last treatment session
|
Changes in neural responses in a cognitive control task before the first and after the last treatment session
Time Frame: Up to 5 weekdays before the first and after the last treatment session
|
Measured with functional magnetic resonance imaging (fMRI) while performing a cognitive control task
|
Up to 5 weekdays before the first and after the last treatment session
|
Changes in behavioral responses in an interoception task before the first and after the last treatment session
Time Frame: Up to 5 weekdays before the first and after the last treatment session
|
Measured as performance in an interoception task during fMRI
|
Up to 5 weekdays before the first and after the last treatment session
|
Changes in behavioral responses in a cognitive control task before the first and after the last treatment session
Time Frame: Up to 5 weekdays before the first and after the last treatment session
|
Measured as performance in a cognitive control task during fMRI
|
Up to 5 weekdays before the first and after the last treatment session
|
Changes in sleep staging over the treatment course
Time Frame: 2 days of baseline measurement before the first iTBS session, daily over the treatment course for 10 days
|
electroencephalography (EEG)-based sleep staging measured with a headband device with accelerometer and pulseoximeter
|
2 days of baseline measurement before the first iTBS session, daily over the treatment course for 10 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in brain connectivity measures
Time Frame: Up to 5 weekdays before the first and after the last treatment session
|
Structural and functional connectivity measured with MRI including graph measures
|
Up to 5 weekdays before the first and after the last treatment session
|
Changes in vigilance over the treatment course
Time Frame: Baseline immediately before the first iTBS session, daily over the treatment course for 10 days
|
Vigilance measured by Psychomotor Vigilance Task (PVT)
|
Baseline immediately before the first iTBS session, daily over the treatment course for 10 days
|
Changes in symptom severity over treatment course
Time Frame: Baseline immediately before the first iTBS session, after 1 week of treatment, after 2 weeks of treatment, and at the follow-up 6 weeks after treatment
|
Measured by the MADRS
|
Baseline immediately before the first iTBS session, after 1 week of treatment, after 2 weeks of treatment, and at the follow-up 6 weeks after treatment
|
Changes in self-reported symptom severity over treatment course and at follow-up
Time Frame: Baseline immediately before the first iTBS session, daily over the treatment course for 10 days, 6 weeks after last iTBS session at the follow-up
|
measured by the Beck Depression Inventory (BDI-II)
|
Baseline immediately before the first iTBS session, daily over the treatment course for 10 days, 6 weeks after last iTBS session at the follow-up
|
Changes in Cortisol Awakening Response (CAR) from saliva concentrations
Time Frame: Up to 5 weekdays before the first and after the last treatment session
|
3 measurements after awakening (0,20, and 40 minutes)
|
Up to 5 weekdays before the first and after the last treatment session
|
Changes in blood parameters
Time Frame: Before the first and after the last treatment session
|
Pro- and anti-inflammatory cytokines, and growth factors
|
Before the first and after the last treatment session
|
Association between changes induced by the Forecaster session and treatment outcome
Time Frame: Immediately before and after the forecaster iTBS session
|
Changes in biomarkers before and after the forecaster iTBS session
|
Immediately before and after the forecaster iTBS session
|
Changes in self-reported BPD symptom severity over treatment course and at follow-up
Time Frame: Baseline immediately before the first iTBS session, daily over the treatment course for 10 days, 6 weeks after last iTBS session at follow-up
|
Measured by the Borderline Symptom List (BSL-23) (range 0-4)
|
Baseline immediately before the first iTBS session, daily over the treatment course for 10 days, 6 weeks after last iTBS session at follow-up
|
Changes in BPD symptom severity over treatment course and at follow-up
Time Frame: Baseline immediately before the first iTBS session, after 1 week of treatment, and after 2 weeks of treatment
|
Measured by Zan-BPD
|
Baseline immediately before the first iTBS session, after 1 week of treatment, and after 2 weeks of treatment
|
Changes in food craving
Time Frame: Up to 5 weekdays before the first and after the last treatment session
|
Measured by a behavioral food craving task
|
Up to 5 weekdays before the first and after the last treatment session
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: René Hurlemann, Prof., Department of Psychiatry, University of Oldenburg
- Principal Investigator: Dirk Scheele, Dr., Department of Psychiatry, University of Oldenburg
- Study Director: Christina Mueller, M.Sc., Department of Psychiatry, University of Oldenburg
- Study Director: Marc Onken, M.Sc., Department of Psychiatry, University of Oldenburg
Publications and helpful links
General Publications
- Blumberger DM, Vila-Rodriguez F, Thorpe KE, Feffer K, Noda Y, Giacobbe P, Knyahnytska Y, Kennedy SH, Lam RW, Daskalakis ZJ, Downar J. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet. 2018 Apr 28;391(10131):1683-1692. doi: 10.1016/S0140-6736(18)30295-2. Epub 2018 Apr 26. Erratum In: Lancet. 2018 Jun 23;391(10139):e24.
- Franzen PL, Buysse DJ. Sleep disturbances and depression: risk relationships for subsequent depression and therapeutic implications. Dialogues Clin Neurosci. 2008;10(4):473-81. doi: 10.31887/DCNS.2008.10.4/plfranzen.
- Rock PL, Roiser JP, Riedel WJ, Blackwell AD. Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med. 2014 Jul;44(10):2029-40. doi: 10.1017/S0033291713002535. Epub 2013 Oct 29.
- Mutz J, Vipulananthan V, Carter B, Hurlemann R, Fu CHY, Young AH. Comparative efficacy and acceptability of non-surgical brain stimulation for the acute treatment of major depressive episodes in adults: systematic review and network meta-analysis. BMJ. 2019 Mar 27;364:l1079. doi: 10.1136/bmj.l1079.
- Tsuno N, Besset A, Ritchie K. Sleep and depression. J Clin Psychiatry. 2005 Oct;66(10):1254-69. doi: 10.4088/jcp.v66n1008.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DREAMS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Disorder
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
University Hospital, MontpellierCompletedMajor Depressive Disorders
Clinical Trials on intermittent theta burst stimulation (iTBS) or sham stimulation
-
University of NottinghamRecruitingFeasibility of Neuromodulation With Connectivity-Guided iTBS for Cognitive Impairment in MS (TMS4MS)Multiple Sclerosis | Cognitive ImpairmentUnited Kingdom
-
The Hong Kong Polytechnic UniversityCompleted
-
King's College LondonSouth London and Maudsley NHS Foundation TrustWithdrawnBinge-Eating DisorderUnited Kingdom
-
Fabio FerrarelliNational Institute of Mental Health (NIMH)RecruitingSchizophreniaUnited States
-
Jean-Marie AnnoniCompleted
-
Hôpital le VinatierTerminated
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruiting
-
Chang Gung Memorial HospitalUnknown
-
Ruijin HospitalRecruitingParkinson Disease | Neuroprotection | Intermittent Theta Burst StimulationChina
-
Uppsala UniversityRecruitingDepression | Pregnancy RelatedSweden